Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1).
Division of Neuroscience, New England Primate Research Center, Harvard Medical School, 1 Pine Hill Drive, Southborough, Massachusetts 01772, USA. gmiller@hms.harvard.edu
Gregory M
GM
Miller
D000818:Animals; D017660:Autoreceptors / Q000502:physiology; D001921:Brain / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000502:physiology; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D011493:Protein Kinase C / Q000502:physiology; D017982:Receptors, Biogenic Amine / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000502:physiology; D015398:Signal Transduction; D050493:Vesicular Monoamine Transport Proteins / Q000378:metabolism; D000095383:Trace Amine-Associated Receptors
D017660:Autoreceptors; D000697:Central Nervous System Stimulants; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C; D017982:Receptors, Biogenic Amine; D043562:Receptors, G-Protein-Coupled; D050493:Vesicular Monoamine Transport Proteins; D000095383:Trace Amine-Associated Receptors